Alwin KrÃ¤mer

List of Publications by Year
in descending order

64 papers	2,311 citations	257357 24 h-index	233338 45 g-index
65 all docs	65 docs citations	65 times ranked	4296 citing authors

#	Article	IF	Citations
1	Prediction of acute myeloid leukaemia risk in healthy individuals. Nature, 2018, 559, 400-404.	13.7	617
2	Requirement for CDK6 in MLL-rearranged acute myeloid leukemia. Blood, 2014, 124, 13-23.	0.6	139
3	RUNX1-mutated families show phenotype heterogeneity and a somatic mutation profile unique to germline predisposed AML. Blood Advances, 2020, 4, 1131-1144.	2.5	102
4	Centrosome clustering and chromosomal (in)stability: A matter of life and death. Molecular Oncology, 2011, 5, 324-335.	2.1	98
5	Polymorphisms of the tumor necrosis factor-Î± gene promoter predict for outcome after thalidomide therapy in relapsed and refractory multiple myeloma. Blood, 2002, 100, 2263-2265.	0.6	91
6	Does time from diagnosis to treatment affect the prognosis of patients with newly diagnosed acute myeloid leukemia?. Blood, 2020, 136, 823-830.	0.6	85
7	JAK2-V617F mutation in a patient with Philadelphia-chromosome-positive chronic myeloid leukaemia. Lancet Oncology, The, 2007, 8, 658-660.	5.1	72
8	Clonal Heterogeneity As Detected by Metaphase Karyotyping Is an Indicator of Poor Prognosis in Acute Myeloid Leukemia. Journal of Clinical Oncology, 2013, 31, 3898-3905.	0.8	63
9	Response to thalidomide in progressive multiple myeloma is not mediated by inhibition of angiogenic cytokine secretion. British Journal of Haematology, 2001, 115, 605-608.	1.2	62
10	Centrosome amplification, chromosomal instability and cancer: mechanistic, clinical and therapeutic issues. Chromosome Research, 2016, 24, 105-126.	1.0	59
11	Marker chromosomes can arise from chromothripsis and predict adverse prognosis in acute myeloid leukemia. Blood, 2017, 129, 1333-1342.	0.6	57
12	Asymmetric Centriole Numbers at Spindle Poles Cause Chromosome Missegregation in Cancer. Cell Reports, 2017, 20, 1906-1920.	2.9	49
13	A Challenging Task: Identifying Patients with Cancer of Unknown Primary (CUP) According to ESMO Guidelines: The CUPISCO Trial Experience. Oncologist, 2021, 26, e769-e779.	1.9	48
14	Molecular driver alterations and their clinical relevance in cancer of unknown primary site. Oncotarget, 2016, 7, 44322-44329.	0.8	47
15	Diagnosis and management of metastatic neoplasms with unknown primary. Seminars in Diagnostic Pathology, 2018, 35, 199-206.	1.0	46
16	HDP-101, an Anti-BCMA Antibodyâ€“Drug Conjugate, Safely Delivers Amanitin to Induce Cell Death in Proliferating and Resting Multiple Myeloma Cells. Molecular Cancer Therapeutics, 2021, 20, 367-378.	1.9	42
17	Does Cancer of Unknown Primary (CUP) Truly Exist as a Distinct Cancer Entity?. Frontiers in Oncology, 2019, 9, 402.	1.3	38
18	Safety and efficacy of BAY1436032 in IDH1-mutant AML: phase I study results. Leukemia, 2020, 34, 2903-2913.	3.3	38

#	Article	IF	Citations
19	Gene-targeted CEP164-deficient cells show a ciliation defect with intact DNA repair capacity. Journal of Cell Science, 2016, 129, 1769-74.	1.2	36
20	Sorafenib Versus Placebo in Addition to Standard Therapy in Younger Patients with Newly Diagnosed Acute Myeloid Leukemia: Results from 267 Patients Treated in the Randomized Placebo-Controlled SAL-Soraml Trial. Blood, 2014, 124, 6-6.	0.6	34
21	Cytogenetic intraclonal heterogeneity of plasma cell dyscrasia in AL amyloidosis as compared with multiple myeloma. Blood Advances, 2018, 2, 2607-2618.	2.5	33
22	RNA-Based Detection of Gene Fusions in Formalin-Fixed and Paraffin-Embedded Solid Cancer Samples. Cancers, 2019, 11, 1309.	1.7	32
23	Rituximab maintenance improves survival in male patients with diffuse large B-cell lymphoma. Results of the HD2002 prospective multicentre randomized phase III trial. British Journal of Haematology, 2015, 171, 710-719.	1.2	30
24	The RUNX1 database (RUNX1db): establishment of an expert curated RUNX1 registry and genomics database as a public resource for familial platelet disorder with myeloid malignancy. Haematologica, 2021, 106, 3004-3007.	1.7	29
25	Patients With Cancer of Unknown Primary. Deutsches Ärzteblatt International, 2014, 111, 481-7.	0.6	25
26	Pharmacological Inhibition of Centrosome Clustering by Slingshot-Mediated Cofilin Activation and Actin Cortex Destabilization. Cancer Research, 2016, 76, 6690-6700.	0.4	24
27	Comparative genetic profiling aids diagnosis and clinical decision making in challenging cases of CUP syndrome. International Journal of Cancer, 2019, 145, 2963-2973.	2.3	24
28	Preclinical efficacy of sepantronium bromide (YM155) in multiple myeloma is conferred by down regulation of Mcl-1. Oncotarget, 2014, 5, 10237-10250.	0.8	22
29	Phase I doseâ€escalation trial investigating volasertib as monotherapy or in combination with cytarabine in patients with relapsed/refractory acute myeloid leukaemia. British Journal of Haematology, 2019, 184, 1018-1021.	1.2	21
30	TP53 deficiency permits chromosome abnormalities and karyotype heterogeneity in acute myeloid leukemia. Leukemia, 2019, 33, 2619-2627.	3.3	19
31	Safety and efficacy of vismodegib in relapsed/refractory acute myeloid leukaemia: results of a phase Ib trial. British Journal of Haematology, 2019, 185, 595-598.	1.2	19
32	Severe Dysbiosis and Specific Haemophilus and Neisseria Signatures as Hallmarks of the Oropharyngeal Microbiome in Critically Ill Coronavirus Disease 2019 (COVID-19) Patients. Clinical Infectious Diseases, 2022, 75, e1063-e1071.	2.9	18
33	Micronucleus formation in human cancer cells is biased by chromosome size. Genes Chromosomes and Cancer, 2019, 58, 392-395.	1.5	17
34	Molecular profiling and clinical implications of patients with acute myeloid leukemia and extramedullary manifestations. Journal of Hematology and Oncology, 2022, 15, 60.	6.9	17
35	Clinical Outcomes in Patients with FLT3-ITD-Mutated Relapsed/Refractory Acute Myelogenous Leukemia Undergoing Hematopoietic Stem Cell Transplantation after Quizartinib or Salvage Chemotherapy in the QuANTUM-R Trial. Transplantation and Cellular Therapy, 2021, 27, 153-162.	0.6	16
36	Synthesis and formulation studies of griseofulvin analogues with improved solubility and metabolic stability. European Journal of Medicinal Chemistry, 2017, 130, 240-247.	2.6	14

#	Article	IF	Citations
37	Integrated clinicomolecular characterization identifies RAS activation and CDKN2A deletion as independent adverse prognostic factors in cancer of unknown primary. International Journal of Cancer, 2020, 146, 3053-3064.	2.3	14
38	Characteristics and outcome of patients with low-/intermediate-risk acute promyelocytic leukemia treated with arsenic trioxide - an international collaborative study. Haematologica, 2021, 106, 3100-3106.	1.7	14
39	A phase 1 study of IDH305 in patients with IDH1R132-mutant acute myeloid leukemia or myelodysplastic syndrome. Journal of Cancer Research and Clinical Oncology, 2023, 149, 1145-1158.	1.2	14
40	Local ablative treatment with surgery and/or radiotherapy in single-site and oligometastatic carcinoma of unknown primary. European Journal of Cancer, 2021, 157, 179-189.	1.3	13
41	Germline genetics of cancer of unknown primary (CUP) and its specific subtypes. Oncotarget, 2016, 7, 22140-22149.	0.8	12
42	<scp>CD</scp>7 is expressed on a subset of normal <scp>CD</scp>34â€positive myeloid precursors. European Journal of Haematology, 2018, 101, 318-325.	1.1	6
43	SMC3 protein levels impact on karyotype and outcome in acute myeloid leukemia. Leukemia, 2019, 33, 795-799.	3.3	6
44	Genomic profiling of carcinomas of unknown primary (CUP) to support clinical decisions.. Journal of Clinical Oncology, 2018, 36, e24162-e24162.	0.8	6
45	Clinical impact of <scp>KMT</scp>2C and <scp>SPRY</scp>4 expression levels in intensively treated younger adult acute myeloid leukemia patients. European Journal of Haematology, 2017, 99, 544-552.	1.1	5
46	A phase I trial investigating the Aurora B kinase inhibitor BI 811283 in combination with cytarabine in patients with acute myeloid leukaemia. British Journal of Haematology, 2019, 185, 583-587.	1.2	5
47	Adding cetuximab to paclitaxel and carboplatin for first-line treatment of carcinoma of unknown primary (CUP): results of the Phase 2 AIO trial PACET-CUP. British Journal of Cancer, 2021, 124, 721-727.	2.9	5
48	Enasidenib. Recent Results in Cancer Research, 2018, 212, 187-197.	1.8	4
49	Concentrationâ€“QTc analysis of quizartinib in patients with relapsed/refractory acute myeloid leukemia. Cancer Chemotherapy and Pharmacology, 2021, 87, 513-523.	1.1	4
50	Prognostic impact of copy number alterations and tumor mutational burden in carcinoma of unknown primary. Genes Chromosomes and Cancer, 2022, 61, 551-560.	1.5	4
51	JAM-C Expression as a Biomarker to Predict Outcome of Patients with Acute Myeloid Leukemiaâ€”Letter. Cancer Research, 2018, 78, 6339-6341.	0.4	3
52	Cep63 Recruits Cdk1 to the Centrosomeâ€”Letter. Cancer Research, 2015, 75, 777-778.	0.4	2
53	Evolution of a FLT3-TKD mutated subclone at meningeal relapse in acute promyelocytic leukemia. Journal of Physical Education and Sports Management, 2016, 2, a001123.	0.5	2
54	Population Pharmacokinetic Analysis of Quizartinib in Healthy Volunteers and Patients With Relapsed/Refractory Acute Myeloid Leukemia. Journal of Clinical Pharmacology, 2020, 60, 1629-1641.	1.0	2

#	Article	IF	Citations
55	The JmjC-domain protein NO66/RIOX-1 affects the balance between proliferation and maturation in acute myeloid leukemia. Experimental Cell Research, 2021, 402, 112566.	1.2	2
56	Paclitaxel/carboplatin with or without cetuximab for treatment of carcinoma with unknown primary (PACET-CUP): Results of a multi-center randomized phase II AIO trial.. Journal of Clinical Oncology, 2019, 37, 4120-4120.	0.8	2
57	PPM1D Mutations Are Rare in De Novo and Therapy-Related Acute Myeloid Leukemia. Blood, 2018, 132, 1472-1472.	0.6	2
58	Concomitant Chronic Lymphocytic Leukemia and Multiple Myeloma: Proof of Common Clonal Origin. Chinese-German Journal of Clinical Oncology, 2004, 3, 81.	0.1	0
59	GF-15, a Novel Inhibitor of Centrosomal Clustering, Suppresses Tumor Growth in Vivo.. Blood, 2008, 112, 1639-1639.	0.6	0
60	Pre-Transplant Weight Loss and Total Serum Protein Predict Relapse Of Acute Myeloid Leukaemia After Allogeneic Stem Cell Transplantation. Blood, 2013, 122, 3314-3314.	0.6	0
61	Efficacy Of Azacitidine Versus Low-Dose Cytarabine In Patients With Acute Myeloid Leukemia - A Retrospective Single Center Experience. Blood, 2013, 122, 3974-3974.	0.6	0
62	Marker Chromosomes Can Arise from Chromothripsis and Predict Adverse Prognosis in Acute Myeloid Leukemia. Blood, 2016, 128, 2869-2869.	0.6	0
63	High-Throughput Immunofluorescence and Electron Tomography to Characterize Centrosomal Aberrations in Plasma Cell Neoplasia. Blood, 2019, 134, 3077-3077.	0.6	0
64	Impact of Genetic Abnormalities and Measurable Residual Disease Levels on Outcome in Patients with MDS/AML Pre-Emptively Treated with Azacitidine: Correlative Results of the Prospective RELAZA2 Trial. Blood, 2020, 136, 10-11.	0.6	0